|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-2-21
|
|
pubmed:abstractText |
Until recently, cytomegalovirus (CMV) infection represented a major threat to lung transplant recipients. Preliminary studies have shown that antiviral prophylaxis might improve the outcome for these patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
831-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18269330-Adult,
pubmed-meshheading:18269330-Antiviral Agents,
pubmed-meshheading:18269330-Bronchiolitis Obliterans,
pubmed-meshheading:18269330-Chemoprevention,
pubmed-meshheading:18269330-Cytomegalovirus,
pubmed-meshheading:18269330-Cytomegalovirus Infections,
pubmed-meshheading:18269330-Female,
pubmed-meshheading:18269330-Ganciclovir,
pubmed-meshheading:18269330-Humans,
pubmed-meshheading:18269330-Incidence,
pubmed-meshheading:18269330-Lung Transplantation,
pubmed-meshheading:18269330-Male,
pubmed-meshheading:18269330-Survival Rate,
pubmed-meshheading:18269330-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
|
|
pubmed:affiliation |
Department of Internal Medicine, University Hospital, Zurich, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
